Amlodipine/candesartan cilexetil - HanAll BioPharma

Drug Profile

Amlodipine/candesartan cilexetil - HanAll BioPharma

Alternative Names: Amlodipine/candesartan; Candesartan cilexetil/amlodipine - HanAll BioPharma; HL-068

Latest Information Update: 12 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator HanAll Biopharma
  • Class Antihypertensives; Benzimidazoles; Biphenyl compounds; Dihydropyridines; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Cytochrome P 450 enzyme system inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Hypertension

Most Recent Events

  • 08 Dec 2016 HanAll BioPharma plans a phase I bioequivalence trial in Healthy volunteers in South Korea (PO) (NCT02988362)
  • 13 Aug 2015 HanAll has patent protection for amlodipine/candesartan cilexeti
  • 13 Aug 2015 Phase-III clinical trials in Hypertension in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top